Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Organigram GlobalSTU:0OG +20.65%64 Debt-to-Equity is 0.02 as of Mar. 2026, which is 50% below its 10-year median of 0.04. GuruFocus rates STU:0OG with a GF Score™ of 64/100 and a GF Value™ of €1.60 (Possible Value Trap). The stock has 1 warning sign investors should review. Among 812 Drug Manufacturers companies, Organigram Global ranks better than 93.1% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Organigram Global's Debt-to-Equity or its related term are showing as below:
STU:0OG'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.01 Med: 0.04 Max: 0.65
Current: 0.02
During the past 13 years, the highest Debt-to-Equity Ratio of Organigram Global was 0.65. The lowest was -0.01. And the median was 0.04.
STU:0OG's Debt-to-Equity is ranked better than 93.1% of 812
companies
in the Drug Manufacturers industry
Industry Median: 0.275
vs STU:0OG: 0.02
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Organigram Global Debt-to-Equity Related Terms
Organigram Global Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Organigram Global's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Organigram Global's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Organigram Global Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Organigram Global's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Organigram Global's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Organigram Global (STU:0OG) has a Debt-to-Equity of 0.02 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Organigram Global and its competitors. This is 50% below median its historical median of 0.04. According to the industry distribution chart, Organigram Global ranks #56 out of 812 companies in the Drug Manufacturers industry, placing it in the top 6.9%.
Is Organigram Global's Debt-to-Equity too high?
Organigram Global's current Debt-to-Equity of 0.02 is 50% below median its 10-year median of 0.04. The Drug Manufacturers industry median Debt-to-Equity is 0.28. Organigram Global's value of 0.02 is 92.7% below this industry median. Based on the distribution chart, Organigram Global ranks #56 out of 812 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Organigram Global has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Organigram Global's Debt-to-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Organigram Global ranks #56 out of 812 companies for Debt-to-Equity. This places Organigram Global in the top 7% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.28. Organigram Global's value of 0.02 is 92.7% below this benchmark. While the company's 10-year median is 0.04 vs. the industry median of 0.28, Organigram Global has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Organigram Global's current Debt-to-Equity of 0.02 is 92.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Organigram Global and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Organigram Global's current Debt-to-Equity is 0.02, which is 50% below median its own 10-year median of 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organigram Global stock overvalued right now?
Based on GuruFocus' analysis, Organigram Global (STU:0OG) is currently considered Possible Value Trap. The stock's GF Value™ is €1.60, compared to a current price of €1.05 — trading 34.6% below its estimated fair value. The current Debt-to-Equity is 0.02, which is 50% below median its 10-year median of 0.04 and 92.7% below the Drug Manufacturers industry median of 0.28. Organigram Global's overall GF Score™ is 64/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Organigram Global (STU:0OG), the current Debt-to-Equity is 0.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Organigram Global (STU:0OG) Overvalued in 2026?
Based on GuruFocus' analysis, Organigram Global stock appears to be undervalued.
The current stock price of €1.05 is trading 34.6% below its estimated GF Value™ of €1.60.
GuruFocus considers Organigram Global to be Possible Value Trap.
Key valuation signals for STU:0OG:
Debt-to-Equity: 0.02 (50% below median its 10-year median of 0.04)
GF Value™: €1.60 vs. price of €1.05 (34.6% below fair value)
Industry Position: 92.7% below the Drug Manufacturers median (#56 of 812)
No single metric tells the full story. See the STU:0OG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Organigram Global Inc is a licensed cultivator of cannabis and manufacturer of cannabis-derived goods in Canada. It is is focused on producing high-quality cannabis for adult recreational consumers. It has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Trailblazer, BOXHOT and DEBUNK. Organigram operates facilities in Moncton, New Brunswick and Lac-Superieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba.
64GF Score
Get the complete analysis for STU:0OG
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:0OG has been successfully added to your 
